

**Cross-group neutralization of HIV-1 and evidence for conservation of the PG9/PG16 epitopes within divergent groups of HIV-1**

Martine Braibant, Eun-Yeung Gong, Jean-Christophe Plantier, François Simon, Francis Barin

► **To cite this version:**

Martine Braibant, Eun-Yeung Gong, Jean-Christophe Plantier, François Simon, Francis Barin. Cross-group neutralization of HIV-1 and evidence for conservation of the PG9/PG16 epitopes within divergent groups of HIV-1. *Retrovirology*, BioMed Central, 2012, 9 (Suppl 2), pp.P53. <inserm-00731773>

**HAL Id: inserm-00731773**

**<http://www.hal.inserm.fr/inserm-00731773>**

Submitted on 13 Sep 2012

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



POSTER PRESENTATION

Open Access

# Cross-group neutralization of HIV-1 and evidence for conservation of the PG9/PG16 epitopes within divergent groups of HIV-1

M Braibant<sup>3</sup>, E Gong<sup>3</sup>, J Plantier<sup>1</sup>, F Simon<sup>2</sup>, F Barin<sup>3\*</sup>

From AIDS Vaccine 2012

Boston, MA, USA. 9-12 September 2012

## Background

HIV-1 has been classified into 4 groups: M, N, O and P. The aim was to revisit the cross-group neutralization using a highly diverse panel of primary isolates (PI) and human monoclonal neutralizing antibodies (mAb).

## Methods

The panel of viruses included 9 HIV-1 group O PIs, 1 recombinant M/O PI, 1 group N PI, 1 group P PI, 2 group M (subtype B) PIs and the HIV-1 group M adapted strain MN. All the viruses were tested for neutralization in TZM-bl cells, using a panel of sera issued from patients infected by HIV-1 group M viruses (n=11), HIV-1 groups O (n=12) and P (n=1). The mAbs were b12, 2G12, 2F5, 4E10, PG9, PG16, VRC01, VRC03 and HJ16.

## Results

The 12 group O sera neutralized from 1 to 6 group O viruses, and 6 of them cross-neutralized one group M PI. Five of the 10 group M sera cross-neutralized from 4 to 9 group O PIs. The group N and P viruses were neutralized by 1-4 of 12 and 4-5 of 11 sera from groups O and M patients, respectively. The human mAbs did not show any cross-group neutralization, except PG9 and PG16. Two group O PIs were neutralized by both PG9 and PG16, and one group O PI was neutralized by PG9 only. The group N PI was highly sensitive to neutralization by PG9 and PG16. The N-linked glycans at positions 156 and 160 and the cationic residues of strand C of the V1/V2 domain that have been identified as part of the PG9 epitope are conserved among the group N.

## Conclusion

The cross-group neutralization of HIV-1 has been demonstrated. The conservation of the PG9 and PG16 epitopes between groups provides an argument for their relevance as components of a potentially efficient HIV vaccine.

## Author details

<sup>1</sup>Charles Nicolle University Hospital, Rouen, France. <sup>2</sup>St Louis Hospital, Paris, France. <sup>3</sup>Universite François Rabelais, and INSERM U966, Tours, France.

Published: 13 September 2012

doi:10.1186/1742-4690-9-S2-P53

**Cite this article as:** Braibant et al.: Cross-group neutralization of HIV-1 and evidence for conservation of the PG9/PG16 epitopes within divergent groups of HIV-1. *Retrovirology* 2012 **9**(Suppl 2):P53.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
www.biomedcentral.com/submit



<sup>3</sup>Universite François Rabelais, and INSERM U966, Tours, France  
Full list of author information is available at the end of the article